ADT Does Not Raise Risk of Heart Attacks In Men With No History Of Heart Disease
Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint
MDV3100 Improves Survival, Reduces Death Risk by 37%
Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication
Elevated Baseline Glucose Levels Associated With Higher Cancer Risk
Oncotype DX Cancer Test Can Predict Recurrence
Signet Cell A Rising Trend In Patients Under Age 40
FIT More Effective Than gFOBT In All Colonoscopy Capacities
Tumor Treating Fields Therapy Increased Three-Year Survival
Only 20 Percent Of At-Risk Patients Are Screened For HBV Before Therapy
New Algorithm Completes Scan Three Times Faster Than Before
Survivorship Studies Unfocused As Total Research Increases
Trials Approved by NCI CTEP Last Month
Agency Approves HPV Test That Detects 14 High-Risk Strains
Alimta Granted Approval As NSCLC Continuation Therapy
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - As more people are surviving cancer, we must continue funding bold science
